Suárez-Roa María de Lourdes, Reveiz Ludovic, Ruíz-Godoy Rivera Luz María, Asbun-Bojalil Juan, Dávila-Serapio José Eduardo, Menjívar-Rubio Andrés H, Meneses-García Abelardo
Section of Pathology, National Cancer Institute, Av. San Fernando, No. 22 Col. Seccion XVI, Mexico City, Mexico, 14080.
Cochrane Database Syst Rev. 2009 Oct 7(4):CD007404. doi: 10.1002/14651858.CD007404.pub2.
Central giant cell granuloma (CGCG) of the jaws is a rare benign tumour with an unknown aetiology accounting for up to 7% of tumours in the mandible (lower jaw) and the maxilla (upper jaw).
This systematic review focused on assessing the effects of primary non-surgical versus primary surgical interventions or any other treatment or placebo for treating central giant cell granuloma of the jaws.
Relevant randomised controlled trials (RCTs) were identified from the Cochrane Oral Health Group's Trials Register (July 2009); CENTRAL (The Cochrane Library 2009, Issue 3); MEDLINE (1950 to July 2009); EMBASE (1980 to July 2009); and LILACS (1982 to July 2009). We scanned bibliographies of relevant studies for possible references to additional trials as well as prospective clinical trial registries. Eligible RCTs were included regardless of the language of publication.
Randomised controlled trials involving a comparison of primary non-surgical interventions with primary surgical interventions or any other treatment.
Two review authors independently assessed eligibility, risk of bias and extracted data. The Cochrane Collaboration statistical guidelines were followed.
We did not find any study evaluating the effects of primary surgical versus primary non-surgical interventions for central giant cell granuloma of the jaws. However, we included and analysed one RCT with unclear risk of bias, evaluating the effects of calcitonin versus placebo for central giant cell granuloma of the jaws. No significant difference was found in the proportion of patients with increased volume of more than 10% of the lesion compared to the pretreatment measurement at 3 months of follow-up (one RCT, 14 participants; risk ratio (RR) 3.00, 95% confidence interval (CI) 0.40 to 22.30).
AUTHORS' CONCLUSIONS: We did not find RCTs evaluating the effects of primary surgical versus primary non-surgical interventions for central giant cell granuloma of the jaws. Although a number of non-surgical therapies have been proposed for treating central giant cell granuloma of the jaws, our review did not identify evidence from RCTs to support their use. More research is needed on this topic.
颌骨中央巨细胞肉芽肿（CGCG）是一种罕见的良性肿瘤，病因不明，占下颌骨（下颌）和上颌骨（上颌）肿瘤的7%。
本系统评价聚焦于评估原发性非手术干预与原发性手术干预或任何其他治疗或安慰剂治疗颌骨中央巨细胞肉芽肿的效果。
从Cochrane口腔健康组试验注册库（2009年7月）、CENTRAL（Cochrane图书馆2009年第3期）、MEDLINE（1950年至2009年7月）、EMBASE（1980年至2009年7月）和LILACS（1982年至2009年7月）中识别相关随机对照试验（RCT）。我们查阅了相关研究的参考文献，以寻找可能的其他试验参考文献以及前瞻性临床试验注册库。无论出版物语言如何，符合条件的RCT均被纳入。
涉及原发性非手术干预与原发性手术干预或任何其他治疗比较的随机对照试验。
两位综述作者独立评估纳入资格、偏倚风险并提取数据。遵循Cochrane协作网的统计指南。
我们未找到任何评估原发性手术与原发性非手术干预对颌骨中央巨细胞肉芽肿效果的研究。然而，我们纳入并分析了一项偏倚风险不明确的RCT，该试验评估了降钙素与安慰剂对颌骨中央巨细胞肉芽肿的效果。在随访3个月时，与治疗前测量相比，病变体积增加超过10%的患者比例未发现显著差异（一项RCT，14名参与者；风险比（RR）3.00，95%置信区间（CI）0.40至22.30）。
我们未找到评估原发性手术与原发性非手术干预对颌骨中央巨细胞肉芽肿效果的RCT。尽管已提出多种非手术疗法治疗颌骨中央巨细胞肉芽肿，但我们的综述未从RCT中找到支持其使用的证据。关于该主题需要更多研究。
